A Form 4 filed on August 14, 2026 discloses that Alaleh Nouri, Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (NASDAQ:PRCT), acquired 22,965 restricted stock units and a stock option covering 31,773 shares of common stock on August 13, 2026.

Key Highlights

  • RSU Grant: Nouri acquired 22,965 RSUs at $0 cost on August 13, 2026, with one-quarter vesting on August 13, 2027 and the remainder vesting quarterly over 36 months.
  • Stock Option Grant: Nouri acquired a stock option to purchase 31,773 shares of common stock at an exercise price of $21.95, expiring August 12, 2036.
  • Option Vesting Schedule: The stock option vests at 1/48th of the shares monthly from a vesting commencement date of August 13, 2026, over a four-year period.
  • Beneficial Ownership Following Transactions: Nouri directly holds 128,034 shares of common stock and 31,773 derivative securities following the reported transactions.
  • Grant Purpose: According to the filing, each grant "is intended to be 50% of the value of the Reporting Person's expected 2027 grant, and made in lieu of such portion of the expected 2027 grant."

Nouri's Equity Awards at PROCEPT BioRobotics: RSUs and Options Detailed

According to the filing, Alaleh Nouri, serving as EVP, CLO, and Corporate Secretary at PROCEPT BioRobotics Corp, received two equity awards on August 13, 2026. The first is a grant of 22,965 restricted stock units, each representing a contingent right to receive one share of common stock, acquired at a price of $0. The filing states that one-quarter of the RSUs will vest on August 13, 2027, with one-sixteenth of the remaining RSUs vesting quarterly over 36 months thereafter, subject to Nouri continuing as a service provider through each applicable vesting date.

The second award is a stock option granting the right to purchase 31,773 shares of common stock at an exercise price of $21.95 per share, with an expiration date of August 12, 2036. The filing discloses that 1/48th of the shares subject to the option vest monthly from the vesting commencement date of August 13, 2026, over a four-year period, contingent on continued employment or service through each vesting date.

The filing notes that both grants are each "intended to be 50% of the value of the Reporting Person's expected 2027 grant, and made in lieu of such portion of the expected 2027 grant." Following these transactions, the filing reports that Nouri directly and beneficially owns 128,034 shares of common stock and holds 31,773 derivative securities. The Form 4 was signed by Jonathan Stone as Attorney-in-Fact for Alaleh Nouri on August 14, 2026.

What Was Disclosed

The filing reports two equity awards granted to PROCEPT BioRobotics Corp's EVP, CLO, and Corporate Secretary on August 13, 2026: 22,965 RSUs and a stock option for 31,773 shares at $21.95, each described as representing 50% of the reporting person's expected 2027 grant.